Redwire's CEO, Peter Cannito, discusses the company's space infrastructure and its focus on building fundamental components for space missions, including power, communication, and navigation systems. A key area of focus is pharmaceutical development using the Pillbox manufacturing capability, which leverages microgravity to grow purer and larger crystals for drug development. Cannito highlights a successful partnership with Eli Lilly, which has led to a second Pillbox mission. He also emphasizes the potential of bioprinting in microgravity to address the organ shortage, noting Redwire's successful printing of a human meniscus on orbit. Additionally, Cannito touches on Redwire's involvement with Blue Origin's Blue Ring project, providing solar arrays and other components. He outlines Redwire's path to profitability through scaling production, moving up the value chain, and exploring venture opportunities like space biotech.
Sign in to continue reading, translating and more.
Continue
